Search Results

There are 13091 results for: content related to: Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

  1. You have free access to this content
    The potential role of Aurora kinase inhibitors in haematological malignancies

    British Journal of Haematology

    Volume 155, Issue 5, December 2011, Pages: 561–579, Sherif S. Farag

    Version of Record online : 8 OCT 2011, DOI: 10.1111/j.1365-2141.2011.08898.x

  2. You have free access to this content
    The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma

    British Journal of Haematology

    Volume 140, Issue 3, February 2008, Pages: 295–302, Robert P. Evans, Claudia Naber, Tara Steffler, Tamara Checkland, Christopher A. Maxwell, Jonathan J. Keats, Andrew R. Belch, Linda M. Pilarski, Raymond Lai and Tony Reiman

    Version of Record online : 10 DEC 2007, DOI: 10.1111/j.1365-2141.2007.06913.x

  3. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma

    Veterinary and Comparative Oncology

    Alexandra Keller, Bettina Wingelhofer, Barbara Peter, Karin Bauer, Daniela Berger, Susanne Gamperl, Martin Reifinger, Sabine Cerny-Reiterer, Richard Moriggl, Michael Willmann, Peter Valent and Emir Hadzijusufovic

    Version of Record online : 11 APR 2017, DOI: 10.1111/vco.12311

  4. You have free access to this content
    An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor

    Clinical and Experimental Pharmacology and Physiology

    Volume 43, Issue 6, June 2016, Pages: 585–601, Cameron T Durlacher, Zhi-Ling Li, Xiao-Wu Chen, Zhi-Xu He and Shu-Feng Zhou

    Version of Record online : 4 MAY 2016, DOI: 10.1111/1440-1681.12571

  5. The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro

    Veterinary and Comparative Oncology

    Volume 14, Issue 1, March 2016, Pages: 13–27, K. Shiomitsu, E. Sajo, C. Rubin and I. Sehgal

    Version of Record online : 13 JUN 2013, DOI: 10.1111/vco.12046

  6. You have full text access to this Open Access content
    AURKA regulates JAK2–STAT3 activity in human gastric and esophageal cancers

    Molecular Oncology

    Volume 8, Issue 8, December 2014, Pages: 1419–1428, Ahmed Katsha, Janet Arras, Mohammed Soutto, Abbes Belkhiri, Wael El-Rifai

    Version of Record online : 3 JUN 2014, DOI: 10.1016/j.molonc.2014.05.012

  7. The effects of baicalein on canine osteosarcoma cell proliferation and death

    Veterinary and Comparative Oncology

    Volume 12, Issue 4, December 2014, Pages: 299–309, E. C. Helmerick, J. P. Loftus and J. J. Wakshlag

    Version of Record online : 10 DEC 2012, DOI: 10.1111/vco.12013

  8. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 10, October 2013, Pages: 923–930, A. Kiyosue, N. Hayashi, H. Komori, M. Leonsson-Zachrisson and E. Johnsson

    Version of Record online : 22 APR 2013, DOI: 10.1111/dom.12100

  9. You have free access to this content
    Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism

    International Journal of Cancer

    Volume 131, Issue 11, 1 December 2012, Pages: 2693–2703, Kevin R. Kelly, Steffan T. Nawrocki, Claudia M. Espitia, Mengkun Zhang, Johnny J. Yang, Swaminathan Padmanabhan, Jeffrey Ecsedy, Francis J. Giles and Jennifer S. Carew

    Version of Record online : 28 JUN 2012, DOI: 10.1002/ijc.27579

  10. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 11, November 2014, Pages: 1096–1101, A. J. Krentz, L. Morrow, M. Petersson, E. Norjavaara and M. Hompesch

    Version of Record online : 3 JUL 2014, DOI: 10.1111/dom.12323

  11. Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy

    Medicinal Research Reviews

    Volume 36, Issue 6, November 2016, Pages: 1036–1079, Min Yan, Chunli Wang, Bin He, Mengying Yang, Mengying Tong, Zijie Long, Bing Liu, Fei Peng, Lingzhi Xu, Yan Zhang, Dapeng Liang, Haixin Lei, Sen Subrata, Keith W. Kelley, Eric W.-F. Lam, Bilian Jin and Quentin Liu

    Version of Record online : 13 JUL 2016, DOI: 10.1002/med.21399

  12. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 8, August 2013, Pages: 750–759, J. P. H. Wilding, M. Leonsson-Zachrisson, C. Wessman and E. Johnsson

    Version of Record online : 24 MAR 2013, DOI: 10.1111/dom.12088

  13. Antagonism of serotonin receptor 1B decreases viability and promotes apoptosis in the COS canine osteosarcoma cell line

    Veterinary and Comparative Oncology

    Volume 14, Issue 2, June 2016, Pages: e31–e44, A. K. Viall, C. P. Goodall, B. Stang, K. Marley, P. E. Chappell and S. Bracha

    Version of Record online : 10 JUN 2014, DOI: 10.1111/vco.12103

  14. Discovery of AZD1152: A Selective Inhibitor of Aurora-B Kinase with Potent Antitumor Activity

    Kinase Inhibitor Drugs

    Kevin M. Foote, Andrew A. Mortlock, Pages: 309–332, 2009

    Published Online : 28 SEP 2009, DOI: 10.1002/9780470524961.ch12

  15. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 12, December 2012, Pages: 1114–1122, L. A. Morrow, M. Leonsson-Zachrisson, H. Ericsson, M. Wollbratt, M. Knutsson, M. Hompesch and E. Norjavaara

    Version of Record online : 31 JUL 2012, DOI: 10.1111/j.1463-1326.2012.01661.x

  16. The 5-lipoxygenase inhibitor tepoxalin induces oxidative damage and altered PTEN status prior to apoptosis in canine osteosarcoma cell lines

    Veterinary and Comparative Oncology

    Volume 14, Issue 2, June 2016, Pages: e17–e30, J. P. Loftus, D. Cavatorta, J. J. Bushey, C. B. Levine, C. S. Sevier and J. J. Wakshlag

    Version of Record online : 11 MAY 2014, DOI: 10.1111/vco.12094

  17. You have free access to this content
    Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells

    FEBS Letters

    Volume 585, Issue 12, June 23, 2011, Pages: 1884–1890, Kazuya Sumi, Kenji Tago, Tadashi Kasahara and Megumi Funakoshi-Tago

    Version of Record online : 8 MAY 2011, DOI: 10.1016/j.febslet.2011.04.068

  18. You have full text access to this OnlineOpen article
    Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence

    EMBO Molecular Medicine

    Volume 5, Issue 1, January 2013, Pages: 149–166, Yan Liu, Oriana E. Hawkins, Yingjun Su, Anna E. Vilgelm, Tammy Sobolik, Yee-Mon Thu, Sara Kantrow, Ryan C. Splittgerber, Sarah Short, Katayoun I. Amiri, Jeffery A. Ecsedy, Jeffery A. Sosman, Mark C. Kelley and Ann Richmond

    Version of Record online : 25 NOV 2012, DOI: 10.1002/emmm.201201378

  19. You have free access to this content
    A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma

    British Journal of Haematology

    Volume 170, Issue 6, September 2015, Pages: 886–890, Graham P. Collins, Toby A. Eyre, Kim M. Linton, John Radford, Grant D. Vallance, Elizabeth Soilleux and Chris Hatton

    Version of Record online : 26 FEB 2015, DOI: 10.1111/bjh.13333

  20. You have free access to this content
    Clinicopathologic significance of Aurora kinase A expression in non-small cell lung cancer

    Basic and Applied Pathology

    Volume 5, Issue 1, March 2012, Pages: 8–14, Hee Jeong Lee, Eun Suk Koh, Jeong Ja Kwak, Hee Kyung Kim, Sang-Mo Park and In-Ho Choi

    Version of Record online : 9 FEB 2012, DOI: 10.1111/j.1755-9294.2011.01120.x